A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice.
A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice.
复制标题
DOI：
--
复制
发表时间：
2006
影响因子：
4.4
通讯作者：
T. Chiba;Y. Kondo;Shohei Shinozaki;E. Kaneko;A. Ishigami;N. Maruyama;K. Umezawa;K. Shimokado
中科院分区：
文献类型：
--
作者：
T. Chiba;Y. Kondo;Shohei Shinozaki;E. Kaneko;A. Ishigami;N. Maruyama;K. Umezawa;K. Shimokado
背景与目的动脉粥样硬化是一种慢性炎症过程，抗炎药可能抑制动脉粥样硬化的发展。我们测试了一种新的NFkappaB抑制剂是否可以减少动脉粥样硬化。方法对apoE缺陷小鼠给予脱羟甲基氧奎诺米星(10 mg/kg)或赋形剂(氯甲基纤维素)，每周3次，共16周。在4周和16周时切除整个主动脉，并测定动脉粥样硬化面积。同时检测血清胆固醇、甘油三酯、肿瘤坏死因子-α和脂联素水平。结果给予脱羟甲基环氧奎诺米星治疗4周和16周的小鼠动脉粥样硬化面积均显著小于对照组。在体重或血清胆固醇、甘油三酯和脂联素水平方面没有显著差异。结论新型NFkappaB抑制剂脱羟甲基氧奎诺米星可在不影响apoE基因缺陷小鼠血脂水平的情况下减轻动脉粥样硬化。
BACKGROUND AND PURPOSE Atherosclerosis is a chronic inflammatory process, and anti-inflammatory agents potentially inhibit the development of atherosclerosis. We tested whether a novel NFkappaB inhibitor reduces atherosclerosis. METHODS Dehydroxymethylepoxyquinomicin (10 mg/kg) or vehicle (chloromethyl cellulose) was injected intraperitoneally into apoE-deficient mice three times a week for 16 weeks. The entire aorta was excised and atherosclerotic area was determined at 4 and 16 weeks. Serum levels of cholesterol, triglyceride, TNF-alpha and adiponectin were also measured. RESULTS The atherosclerotic area was significantly smaller in mice treated with dehydroxymethyl-epoxyquinomicin both at 4 and 16 weeks. There was no significant difference in body weight or serum levels of cholesterol, triglyceride, and adiponectin. CONCLUSIONS A new NFkappaB inhibitor, dehydroxymethylepoxyquinomicin, reduced atherosclerosis without affecting plasma lipid levels in apoE-deficient mice.